Department of Biostatistical Science

1997 Publications

Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 1997; 57:1769-1775.

Catalano PJ. Bivariate modelling of clustered continuous and ordered categorical outcomes. Stat Med. 1997; 16:883-900.

Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997; 15:3100-3110.

Dreicer R, Propert KJ, Roth BJ, Einhorn LH, Loehrer PJ. Vinblastine, ifosfamide, and gallium nitrate-an active new regimen in patients with advanced carcinoma of the urothelium. (A Phase II Trial of the Eastern Cooperative Oncology Group (E5892)). Cancer 1997; 79:110-4.

Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of Edatrexate in patients with advanced renal cell carcinoma. An ECOG study. Am J Clin Oncol 1997; 20(3):251-253.

Ewell M, Ibrahim JG. The large sample distribution of the weighted log rank statistic under general local alternatives. Lifetime Data Analysis 1997; 3:5-12.

Fairclough DL Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16:1197-1209.

Fine HA, Wen PY, Robertson M, O'Neill A, Kowal J, Loeffler JS, Black PML. A phase I trial of a new recombinant human -interferon (BG9015) for the treatment of patients with recurrent gliomas. Clinical Cancer Research 1997; 3:381-387.

Gollamudi SV, Gelman RS, Peiro G, Schneider LJ, Schnitt SJ, Recht A, Silver BJ, Harris JR, Connolly JL. Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma. Cancer 1997; 79:1362-9.

Hayman JA, Fairclough DL, Harris JR, Weeks JC. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 1997; 15:1252-1260.

Ibrahim JG, Chen M-H. Predictive variable selection for the multivariate linear model. Biometrics 1997; 53:465-478.

International Breast Cancer Study Group (R. Gelber-Study Statistician). Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15:1385-1394.

Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restagining gallium scans predict outcome in poor-prognosis patients with aggressive non-hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631-1637.

Killingsworth CR, Alessandrini F, Krishna Murthy GG, Catalano PJ. Paulauskis JD, Godleski JJ. Inflammation, chemokine expression, and death in monocrotaline-treated rats following fuel oil fly ash inhalation. Inhalation Toxicology 1997; 9:541-565.

Klar N, Donner A. The merits of matching in community intervention trials: a cautionary tale. Statist Med 1997; 16:1753-1764.

Leaf AN, Neuberg D, Schwart EL, Wadler S, Ritch PS, Dutcher JP, Adams GL. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Investigational New Drugs 1997; 15:165-172.

Legler JM, Ryan LM. Latent variable models for teratogenesis using multiple binary outcomes. J Am Stat Assoc 1997; 92:13-20.

Loehrer PJ, Chen M, Kim KM, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, Doxorubicin, and Cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997; 15:3093-3099.

O'Gorman MR, Gelman R, Site Investigators, NIAID New CD4 Technologies Focus Group. Inter- and Intrainstitutional evaluation of autmomated volumetric capillary cytometry for the quantitation of CD4- and CD8- positive T lymphocytes in the peripheral blood of persons infected with human immunodeficiency virus. Clinical and Diagnostic Laboratory Immunology 1997; 173-179.

Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma. Cancer 1997; 79:1561-7.

Olson JE, Neuberg D. Postmastectomy radiation. A modest benefit prevails for high risk patients---reply. Cancer l997; 79:1067-1068.

Olson JE, Neuberg D, Pandya KJ, Richter MP, Solin LJ, Gilchrist KW, Tormey DC, Veeder M, Falkson G. The role of radiotherapy in the management of operable locally advanced breast carcinoma. Cancer 1997; 79:1138-49.

Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, Brunzell JD, Otvos JD, Sallan SE, Rifai N. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997; 89:1886-1895.

Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Casiglione-Gertsch M, Allegra CJ, Johnston PG. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997; 15:1923-1931.

Sammel MD, Ryan LM, Legler JM. Latent variable models for mixed discrete and continuous outcomes. JR Statist Soc B 1997; 59:667-678.

Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-2569.

Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossmna, RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997; 89:3039-3047.

Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1997; 15:1880-1884.

Troxel AB, Lipsitz SR, Brennan TA. Weighted estimating equations with nonignorably missing response data. Biometrics 1997; 53: 857-869.

Weiss RE, Wang Y, Ibrahim JG. Predictive model selection for repeated measures random effects models using Bayes factors. Biometrics 1997; 53: 592-602.

Weller EA, Ryan LM, Spiegelman D, Smith T. Statistical issues in assessing human population exposures. Chemometrics and Intelligent Laboratory Systems 1997; 37:189-195.

Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IF, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E III, Kadin M, Antin J. High-dose cyclophosphamide, carumustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biology of Blood and Marrow Transplantation 1997; 3:98-106.

Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15:2518-2525.

Zackin R, Wei LJ. Analysis of repeated virological measurement based on cell dilution assays. Stat Med 1997; 16:571-582.